Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential by El-Andaloussi, N (author) et al.
Generation of an Adenovirus-Parvovirus Chimera with Enhanced
Oncolytic Potential
Nazim El-Andaloussi,a Serena Bonifati,a Johanna K. Kaufmann,b Laurent Mailly,c* Laurent Daefﬂer,a François Deryckère,c
Dirk M. Nettelbeck,b Jean Rommelaere,a and Antonio Marchinia
Tumour Virology Division F010, German Cancer Research Center (DKFZ), Heidelberg, Germanya; Helmholtz-University Group Oncolytic Adenoviruses, German Cancer
Research Center (DKFZ), and Dept. of Dermatology, Heidelberg University Hospital, Heidelberg, Germanyb; and Unité Mixte de Recherche 7175, Ecole Supérieure de
Biotechnologie de Strasbourg, Illkirch, Francec
In this study, our goal was to generate a chimeric adenovirus-parvovirus (Ad-PV) vector that combines the high-titer and effi-
cient gene transfer of adenovirus with the anticancer potential of rodent parvovirus. To this end, the entire oncolytic PV genome
was inserted into a replication-defective E1- and E3-deleted Ad5 vector genome. As we found that parvoviralNS expression in-
hibited Ad-PV chimera production, we engineered the parvoviral P4 early promoter, which governsNS expression, by inserting
into its sequence tetracycline operator elements. As a result of these modifications, P4-driven expression was blocked in the
packaging T-REx-293 cells, which constitutively express the tetracycline repressor, allowing high-yield chimera production. The
chimera effectively delivered the PV genome into cancer cells, fromwhich fully infectious replication-competent parvovirus par-
ticles were generated. Remarkably, the Ad-PV chimera exerted stronger cytotoxic activities against various cancer cell lines, com-
pared with the PV and Ad parental viruses, while being still innocuous to a panel of tested healthy primary human cells. This
Ad-PV chimera represents a novel versatile anticancer agent which can be subjected to further genetic manipulations in order to
reinforce its enhanced oncolytic capacity through arming with transgenes or retargeting into tumor cells.
Adenoviruses (Ads) are nonenveloped, icosahedral viruseswith a 30- to 38-kbp DNA genome. As of today, over 50 dif-
ferent human serotypes have been described, with most of them
infecting the respiratory or gastrointestinal tracts and the eye (33).
Ad infections are very common and generally not associated with
any serious pathogenicity. Ads represent the most popular gene
therapy vectors andwere used in about 25%of approvedphase I to
III clinical trials for vaccine and therapeutic gene transfer during
the last 2 decades (9). This is largely due to the ability of these
vectors to efficiently deliver transgenes to the nucleus of a wide
range of different cell types and mediate high levels of expression
of the transgene of interest (33). Ads transduce both proliferating
and resting/differentiated cells and remain episomal, which min-
imizes the risk of insertional mutagenesis (33). Furthermore, Ads
are very versatile tools with remarkable DNA packaging capacity,
offering a plethora of possibilities for genetic manipulations. The
Ad genome can be modified in different ways in order to restrict
transgene expression to specific tumor cells (22). Furthermore, it
is possible to redirect Ad entry and render it more specific for
cancer cells, through the use of molecular adaptors or genetic
engineering of the Ad capsid (11, 12, 29). Importantly, Ads can be
produced and purified at high titers and quality under goodman-
ufacturing practice (GMP) conditions (29).
Autonomous rodent parvoviruses (PVs) are small icosahedral,
nonenveloped single-stranded DNA viruses. Their genome is
about 5.1 kb long and contains two promoters, P4 and P38, that
control the expression of the nonstructural (NS1 and NS2) and
structural (VP1 and VP2) proteins, respectively (31). Several PVs,
including the minute virus of mice (MVM) and the rat H-1PV,
have also oncolytic and oncosuppressive properties, as demon-
strated in various cellular and animal cancer models (32). Addi-
tionally, PVs are nonpathogenic and show low prevalence in hu-
mans, favoring their use as therapeutics (5). H-1PV is currently
being evaluated in a phase I and IIa clinical trial for the treatment
of patients with recurrent glioblastoma multiforme (32). The an-
tineoplastic property of these PVs is due, at least in part, to pref-
erential viral DNA replication and gene expression in malignant
cells. This is caused by the virus dependence on the cell cycle S
phase for its replication and, specifically, on cellular factors such as
E2F, CREB, ATF, and cyclin A, which are overexpressed and/or
activated in cancer cells (32). In addition, PVs may counteract the
ability of malignant cells to mount an efficient antiviral innate
immune response (13). It has been shown that PVs have the ability
to induce cell cycle arrest (16) and different death pathways, in-
cluding necrosis (27), apoptosis (16, 26), and lysosome-depen-
dent cell death (8), in cancer cells. Although preclinical studies
highlight the anticancer potential of PVs (32), this property must
be further reinforced in view of the clinical application of these
agents. One major hindrance lies in the fact that PVs bind and
enter into a variety of healthy human cells, resulting in the seques-
tration of a large portion of the administered viral dose away from
the tumor target cells. Retargeting PV entry to tumor cells would
thus increase the efficacy of PV-based treatments and provide ad-
ditional protection against eventual side effects on healthy tissues.
It should be also noted that the difficulty of large-scale production
of PVs, as required for clinical applications, remains a major lim-
itation.
We envisioned that it would be of great benefit to generate an
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Ad-PV chimera combining the unique properties of both vectors.
Similarly to any other recombinant adenovirus vector, the chi-
mera should be produced at high titers, solving the problem of the
difficulty related to the production of parvoviruses. Furthermore,
we recently reported that expression of adenovirus genomic ele-
ments boosted the production of recombinant parvovirus in dif-
ferent cell lines (10). Therefore, we speculated that the Ad-PV
chimera may enhance PV replication in cancer cells through the
concomitant expression of Ad helper functions. In addition, the
principle could be extended to include (i) the specific delivery of
PV genomes to cancer cells bymeans of retargeted Ads and (ii) Ad
genome arming with therapeutic transgenes that potentiate the
PV-killing activity. On the other hand, the PV component of
the chimera would confer antineoplastic activity by (i) expressing
the cytotoxic NS1 protein under the control of its natural PV
promoter and (ii) amplifying the antitumor effect through PV
excision from the vector and autonomous replication and spread-
ing through the tumor.
In the present report, we describe the first generation of Ad-PV
chimeras and their very promising anticancer properties.
MATERIALS AND METHODS
Cells.HEK293 (transformed human embryonic kidney), NB324K (trans-
formed newborn human kidney), and A549 (lung carcinoma) cell lines
were obtained from ATCC (LGC Standards GmBH, Wesel, Germany)
and T-REx-293 from Invitrogen (Darmstadt, Germany). HeLa and SiHa
cervical carcinoma cell lines, positive for human papillomavirus (HPV)
types 18 and 16, respectively, were a gift from Angel Alonso (DKFZ,
Heidelberg, Germany). The ME-180 cell line, positive for HPV 68, was
obtained from Elisabeth Schwarz (DKFZ, Heidelberg, Germany). The co-
lon cancer HCT-15 and HCC-2998 and the melanoma Lox-IMVI cell
lines were from the National Cancer Institute (NCI) (Bethesda, MD).
Low-passage melanoma PMelL cells (purified from skin metastases) have
been previously described (23). The human primary oral fibroblasts and
foreskin fibroblasts were a gift from Massimo Tommasino (IARC, Lyon,
France). Human primary adult melanocytes, lightly pigmented (HEMa-
LP), were from Invitrogen (Carlsbad, CA). Human astrocytes were ob-
tained from ScienCell Research Laboratories (San Diego, CA).
HEK293, HeLa, SiHa, A549, and human primary oral fibroblast cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mentedwith 10% fetal bovine serum (FBS) (Gibco, Invitrogen, Karlsruhe,
Germany). T-REx-293 cells were grown in DMEM containing 10% tetra-
cycline-free certified FBS (PAA, Cölbe, Germany). ME-180 cells were
grown in McCoy’s 5a modified medium supplemented with 10% FBS.
HCT-15, HCC-2998, and Lox-IMVI cells were grown in Roswell Park
Memorial Institute (RPMI) 1640 medium complemented with 10% FBS.
PMelL cells were cultivated in RPMI 1640 (Invitrogen) supplemented
with 10% heat-inactivated fetal bovine serum, 10 mM HEPES (Lonza,
Basel, Switzerland), and 250 ng/ml amphotericin B and 100g/ml genta-
mycin (both from Invitrogen). Human primary foreskin fibroblasts and
NB324K cells were grown inminimum essential medium (MEM) supple-
mented with 10% and 5% FBS, respectively. Primary human adult mela-
nocytes were grown in medium 254 supplemented with HMGS (Invitro-
gen, Carlsbad, CA). Human astrocytes were cultivated in astrocyte
medium (ScienCell Research Laboratories, San Diego, CA). All media,
except the media used to cultivate pMelL and normal melanocytes and
astrocytes, contained 100 U/ml penicillin, 100g/ml streptomycin, and 2
mML-glutamine. Cells were grown at 37°C in 5%CO2 and 92%humidity.
Viruses. hH-1 (17) and hH-1-TO viruses were produced in T-REx-
293 cells. The cells were cultivated in 10-cm-diameter dishes in tetracy-
cline-free medium and transiently transfected at 12.5% confluence with
10 g/dish of either phH-1 or phH-1-TO viral constructs. At 4 h, 3 days,
and 6 days posttransfection, doxycycline (DOX) (1 g/ml) was added to
themedium. At day 7, cells were harvested within their medium and lysed
by 3 freeze-and-thaw cycles and cellular debris was removed by centrifu-
gation. Produced viruseswere further amplified by infectingNB324K cells
and purified through iodixanol gradient centrifugation.
Ad-hH-1-TO and an Ad control (Ad5E1E3) were produced
through 3 rounds of production in T-REx-293 cells cultivated in medium
containing 5% tetracycline-free FBS. In the first round, cells in 12-well
plates were transfected at 75% confluence with 1 g/well of pAd-hH-
1-TOor pAd5E1E3 plasmids predigestedwith PacI. After transfection,
cells were induced with 1 g/ml of DOX or left uninduced. At 5 days
posttransfection, to ensure optimal growth conditions, half of the culture
medium was replaced. At 7 days posttransfection, cells were harvested
into their medium and lysed with 3 freeze-and-thaw cycles and cellular
debris was removed by centrifugation. In the second round, 25% of the
crude viral extract produced in the first round was used to infect T-REx-
293 cells grown in 75-cm2 flasks. At 5 days postinfection (p.i.), half of fresh
medium was added to maintain optimal growth conditions. At 7 days
postinfection, cells were harvested and lysed as previously described. The
third round was comparable to the second round but was carried out
using 175-cm2 flasks. The final viral batches were purified twice through
cesium chloride (CsCl) gradient ultracentrifugation.
DNA cloning. The phH-1-TO parvovirus plasmid was constructed by
inserting two tetracycline operator 2 (TetO2) repressor elements into the
P4 promoter of phH-1 (17), through PCR cloning. In a first step, two
parallel PCRs were carried out, using phH-1 as a template, with the fol-
lowing primers: primer pair PCR1-For (5=-AAACTCGAGGCGGTTCAG
GGAGTTTAAACC-3=) and PCR1-Rev (5=-AACTGACTTCTCTCTATC
ACTGATAGGGAGATCTCTATCACTGATAGGGAAGTAGTTGCTTA
TATACTTTAAACC-3=) and primer pair PCR2-For (5=-AGCAACTACT
TCCCTATCAGTGATAGAGATCTCCCTATCAGTGATAGAGAGAAG
TCAGTTACTTATCTTTTCTTTC-3=) and PCR2-Rev (5=-AAAAAGCTT
CCATCCGATATCTTTTCCATTCAG-3=). In a second step, a third PCR
was carried out using a stochiometric mix of the 2 previous purified PCR
products as the template with PCR1-For and PCR2-Rev as primers. The
DNA product obtained was digested with PmeI and EcoRV and used to
replace the corresponding fragment in phH-1.
pShuttle-cytomegalovirus-free (pShuttle-CMV-free) was constructed
as follows: pShuttle-CMV (Qbiogen, MP Biomedicals, Heidelberg, Ger-
many)was digestedwith BglII, dephosphorylatedwith calf intestine phos-
phatase, and subjected to homologous recombination, in Escherichia coli
BJ5183, with annealed oligonucleotides 5=-GTTCATAGCCCATATATG
GAGTTCAGATCTGGTACCG-3= and 5=-CGGTACCAGATCTGAACT
CCATATATGGGCTATGAAC-3=. pShuttle-hH-1 was generated in 3
steps. (i) In pShuttle-CMV-free, the unique EcoRI site was changed into a
SwaI site, through insertion of the annealed oligonucleotides 5=p-AATT
ATTTA-3= and 5=p-AATTTAAAT-3= at the EcoRI location. (ii) The 5=
region of hH-1 was amplified from phH-1 by PCR using the primers 5=-
AAGGAAAAAAGTCGACTTTTGTGATGCTCGTCA-3= and 5=-AGGA
AAAAAGATATCTTTTCCATTCAGTTGA-3=. The PCR product was di-
gested by SalI and EcoRV (633 bases) and ligated into the previously
modified pShuttle-CMV-free vector, predigested with the same enzymes, re-
sulting in pShuttle-5=hH-1. (iii) The remaining 3= end of the hH-1 genome
(4,730 bases) was excised from the phH-1 plasmid using the EcoRV-NdeI
enzymes, subjected to blunting using a Klenow fragment, and ligated in
EcoRV-digested pShuttle-5=hH-1, generating pShuttle-hH-1.
pShuttle-hH-1-STOP was cloned by inserting 3XSTOP codons into
the unique EcoRV site of the pShuttle-hH-1, located at the beginning of
the parvovirus NS coding sequence. The 3XSTOP DNA duplex was gen-
erated by the self-annealing of the oligonucleotide 5=-TAATAGTGAGAA
TTCTCACTATTA-3=.
pShuttle-hH-1-TO was obtained by replacing the AleI-EcoRV frag-
ment of pShuttle-hH-1 with the corresponding 393-base-long DNA frag-
ment from phH-1-TO.
pAd-hH-1, pAd-hH-1-STOP, and pAd-hH-1-TO were generated by
recombination of pShuttle-hH-1, pShuttle-hH-1-STOP, and pShuttle-
hH-1-TO, respectively, with pAd5E1E3 into E. coli BJ5183, according
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to theAdEasy adenoviral vector system instructionmanual (Agilent Tech-
nologies; Stratagene Products, Waldbronn, Germany).
pAd5E1E3, in which the region encompassing the E1 (nucleotides
[nt] 459 to 3228) and E3 (nt 27897 to 30463) genes (Ad5 Refseq accession
no. AC_000008) was deleted, was constructed as follows. A shuttle plas-
mid containing E3 flanking sequences (18) was digested using MluI and
XbaI, subjected to blunting with a Klenow fragment, and ligated, gener-
ating pLeft-Right. This plasmid was digested with SalI and NotI, dephos-
phorylated, and used for homologous recombination in E. coli BJ5183
with SpeI-linearized pTG3622 (4) from which the E1 region has been
deleted.
All the constructs described here were clonally isolated and their full-
length sequences verified.
Transfections.DNA transfections were carried out using Fugene HD
(RocheDiagnostics &Applied Sciences,Mannheim, Germany) according
to the manufacturer’s instructions with minor modifications. Plasmids
were diluted in serum-free medium to a final concentration of 20 ng/l.
Fugene HD was then added at a 1:2.5 ratio (expressed as the ratio of
micrograms of DNA tomicroliters of Fugene), and the mixture was incu-
bated at room temperature (RT) for 30 to 60 min. Subsequently, the
mixture was added to the cells in a dropwise manner.
Protein extractions and Western blot analysis. Cellular pellets were
lysed on ice for 30 min in 5 volumes of protein extraction buffer (50 mM
Tris [pH 8], 200 mM NaCl, 0.5% NP-40, 1 mM dithiothreitol [DTT])
containing protease inhibitors (Complete EDTA-free; Roche,Mannheim,
Germany) and 10% glycerol. Cell debris was removed by centrifugation at
10,000 rpm for 10min at 4°C. A 20-g volume of total protein extract was
resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) and then transferred onto a Hybond-Pmembrane (GE
Healthcare). The following antibodies were used for the analysis: mouse
monoclonal anti--tubulin (clone TUB 2.1; Sigma-Aldrich, Saint Louis,
MO), mouse monoclonal anti-actin (clone C4; MP Biomedicals, Illkirch,
France), polyclonal anti-NS1 SP8 antiserum (provided by Nathalie Sa-
lomé, ATV-DKFZ, Heidelberg, Germany) (3), and polyclonal anti-VP2
antiserum (a gift from Christiane Dinsart, ATV-DKFZ, Heidelberg, Ger-
many) (17).
Parvovirus titration: plaque assay. NBK cells grown at a density of
20,000 cell/cm2 were infected with serial dilutions of crude virus extracts
for 1 h, followed by replacement of the inoculumwith an overlay of 0.68%
Bacto agar (Becton, Dickinson GmbH, Heidelberg, Germany) in MEM
(Gibco, Invitrogen) supplemented with 5% FBS, 2 mM L-glutamine, 100
U/ml penicillin, and 100 g/ml streptomycin. At 7 days postinfection,
living cells were stained for 18 h with an overlay of neutral-red (0.2 mg/
ml)-containing Bacto agar (0.85%) diluted in phosphate-buffered saline
(PBS). Plaques were counted, and titers were expressed as PFU/milliliter.
Real-time qPCR. Crude virus extracts were digested with 50 U/ml of
Benzonase nuclease (ultrapure grade; Sigma-Aldrich Chemie GmbH,
Steinheim, Germany) for 30 min at 37°C to remove free viral genomic
DNA. To release viral DNA fromviruses, 10l of each sample was lysed in
a total of 40 l of alkaline lysis buffer (1 M NaOH—Tris-EDTA [TE]
buffer) at 56°C for 30 min. Lysis was stopped by adding 960 l of 40 mM
HCl. Quantification of viral DNA was carried out by real-time quantita-
tive PCR (qPCR) with an NS1-specific TaqMan probe (Applied Biosys-
tems, Darmstadt, Germany), as previously described (10). With this
method, we calculated that 1 PFU of hH-1-TO and 1 Adeno IU (see
below) of Ad-hH-1-TO corresponded to approximately 500 and 100 viral
genome-containing particles, respectively.
Adenovirus titration. Recombinant adenovirus titers were deter-
mined using an Adeno-X Rapid Titer kit (Clontech, Saint-Germain-en-
Laye, France), 3 days after infection of T-REx-293 cells (Invitrogen), and
are expressed as infectious units (IU)/ml. Adenovirus IU were measured
using an antibody specific for the adenovirus hexon protein. The yield
values calculated with this method are in good agreement with those ob-
tained by plaque and gene transduction assays (2).
The concentration of adenovirus physical particles was estimated
from the DNA content of the purified viruses, measured by the absor-
bance at 260 nm. An absorbance value of 1 corresponds to 1.1  1012
adenovirus particles/ml (21).
Electron microscopy. Carbon-coated 300-mesh copper grids were
placed face down onto 5-l aliquots of virus suspension for 2min, stained
with 2% uranylacetate for 30 s, and dried for approximately 1 min. Mi-
crographs were taken at 38,000-foldmagnification with a Zeiss 10A trans-
mission electron microscope (Zeiss, Oberkochen, Germany) using an ac-
celeration voltage of 80 kV. The magnification indicator was routinely
controlled by comparison with a grating replica.
Quantification of infection efficiency. Cells were seeded in a 12-well
plate and infected with equal amounts of Ad-green fluorescent protein
(Ad-GFP) or H-1-GFP (10 GFP transduction units [TU]/cell) as previ-
ously quantified using the HEK293T reference cell line. At 48 h and 72 h
p.i., infected cells were harvested by trypsinization and pelleted by centrif-
ugation for 5 min at 1,500 rpm. Samples were washed with PBS, pelleted
again, and then resuspended in 750 l PBS. Cells were analyzed by flow
cytometry (FACSort; Becton, Dickinson, Franklin Lakes, NJ), and per-
centages of GFP-positive cells were determined using FCS Express version
3 (De Novo Software, Los Angeles, CA).
LDH andMTT assays.Human cells were first seeded in 96-well plates
at densities of 4,000 cell/well for cancer cells and 8,000 to 10,000 cell/well
for primary cells. The respective culture media were as described above,
except for melanocytes and astrocytes, which were seeded in DMEM sup-
plementedwith 10%heat-inactivated FBS instead of the artificialmedia in
which they are routinely grown. After infection, all cells were kept in their
corresponding basal medium supplemented with 5% of heat-inactivated
bovine serum (200l/well). Cancer cells and primary cells were incubated
for 4 and 5 days, respectively, and then subjected to lactate dehydrogenase
(LDH) and MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetra-
zolium bromide] assays as previously described (16).
Released LDH was measured according to the CytoTox 96 nonradio-
active cytotoxicity assay (Promega Biotech, Madison, WI), using an en-
zyme-linked immunosorbent assay (ELISA) reader at 492 nm. After sub-
traction of the background value determined with nonconditioned
medium, the fraction of lysed cells in infected or noninfected cultures was
calculated from the ratio of the LDH activity in the conditioned medium
to the total LDH activity of the corresponding culture. The total LDH
activity was determined after cell lysis by the addition of 10 buffer con-
taining 9% (vol/vol) Triton X-100. The same cell cultures were used to
determine LDH release and MTT activity. Activity of MTT (Sigma-Al-
drich Chemie GmbH, Steinheim, Germany) was read with an ELISA
reader at 595 nm. The viability of infected cells was expressed as the ratio
of the corresponding absorbance to that of noninfected cells taken arbi-
trarily as 100%.
Real-time detection of cell proliferation and viability. Cells were
seeded on a 96-well E-Plate (Roche Diagnostics Deutschland GmbH,
Mannheim, Germany) at a density of 4,000 cells/well (or, for HCC-2998,
8,000 cells/well). At 24 h to 72 h later, cells were infected with Ad-hH-1-
TO, Ad5E1E3 (Ad control), or hH-1-TO or the combination of the Ad
control and hH-1-TO viruses. Cellular proliferation, reflecting virus-me-
diated cytopathic and cytostatic effects, was monitored in real time, every
30 min, using an xCelligence System (Roche Diagnostics Deutschland
GmbH, Mannheim, Germany). The growth curves shown represent the
averages of the results of at least three replicate experiments and include
relative standard deviations.
RESULTS
Generation of parvovirus hH-1-TO carrying a tetracycline-in-
ducible P4 promoter. Our first attempts to produce adenovirus
carrying the hybrid Ad-PV genome failed, most likely due to the
interference of the parvovirus NS proteins (data not shown). In-
deed, the introduction of stop codons within theNS open reading
frame could rescue Ad production to standard titers (more than
4 1012 Ad particles/ml were obtained after production and pu-
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rification according to the protocol described in Materials and
Methods). Attempts to rescue Ad-PV chimera production by si-
lencing NS1 expression by means of the use of specific antisense
oligonucleotides, small interfering RNAs (siRNAs), or short hair-
pin RNAs (shRNAs) (used singly or in combination) allowed viral
particles to be produced, and yet the particles were produced in
very small amounts (fewer than 400Adparticleswere produced by
1  107 cells), suggesting that even at low levels, NS1 exerted a
negative effect on Ad production (data not shown). In view of
these results, we decided to modify the parvovirus early P4 pro-
moter, which controls the expression of the NS gene, in order to
tightly control its activity during chimera production. We took
advantage of the T-REx technology (15, 36) and engineered the P4
promoter to make it inducible by inserting two tetracycline oper-
ator 2 elements (TetO2) (36) between the TATA box and the NS
starting codon (Fig. 1). With this modification, we expected to
repress the P4 promoter in T-REx-293 cells that constitutively
express the tetracycline repressor (TetR) in the absence of doxy-
cycline (DOX) and induce the promoter in the presence of the
drug (36). In contrast, in cancer cells which do not express TetR,
the P4 promoter should be fully functional. This modified parvo-
virus was generated and named phH-1-TO.
T-REx-293 cells were transfected with phH-1-TO or parental
phH-1, incubated for 2 days, harvested, and processed for West-
ern blotting detection of parvoviral NS1 and VP proteins. In cells
transfected with the parental phH-1 viral vector, the addition of
DOX did not affect total NS1 protein levels (Fig. 2A). In contrast,
in phH-1-TO-transfected cells, expression of NS1 was induced in
the presence ofDOX, demonstrating that the activity of the P4-TO
promoter is under the control of an on-off switch mechanism.
Under induction conditions, NS1 protein levels were similar to
those observed using the parental viral vector, indicating that the
insertion of the TetO2 did not impair NS production when DOX
was supplied to the cellmedium (Fig. 2A). It is known that theNS1
protein transactivates the parvoviral p38 promoter, which con-
trols the transcription of the VP genes coding for the capsid pro-
teins. In agreement with the repression of NS1 production, only
slight expression of VP1 and VP2 was observed in phH-1-TO-
transfected T-REx-293 cells grown under DOX-free conditions.
In contrast, VPproteins accumulated in these cells whenDOXwas
added to the medium (Fig. 2A).
To assess whether transfection with phH-1-TO also resulted in
the production of infectious progeny virions, T-REx-293 cells
were transfected with phH-1-TO or parental phH-1 constructs
and grown in the presence or absence of DOX for a total of 7 days.
Cell lysates from these cultures were then used for the infection of
NB324K cells. After an additional 7 days, crude cellular extracts
were tested for the presence of full virions able to infect, kill, and
spread in NB324K indicator cells, as measured by a plaque assay.
As expected, the parental hH-1 virus was produced at similar lev-
els irrespective of the presence or absence of DOX. In contrast,
DOX was required during the T-REx-293 transfection phase for
hH-1-TO virions to be produced at a significant level (Fig. 2B),
yielding virus titers comparable to the ones obtained with the
parental virus (data not shown). These results show that TetO2
insertions into the P4 promoter regionmake PVproduction in the
T-REx-293 cells dependent on DOX induction. Moreover, the
insertions are fully compatiblewith the entire course of parvovirus
life cycle, as the de novo-generated hH-1-TO viral particles were
fully infectious and capable of autonomously replicating in cells
like NBK324 that do not express the TetR.
The propagation of hH-1-TO viruses was further investigated
in T-REx-293 cells. Cells were inoculated with either hH-1-TO or
hH-1 viruses and grown in the presence or absence of DOX for 4
days with one medium change at 24 h p.i. in order to eliminate
unbound viral particles. Cells were then lysed into their respective
media, and the parvovirus production was evaluated by a parvo-
virus-specific qPCR. In agreement with the results presented
FIG 1 Construction of an inducible parvovirus P4 promoter (P4-TO). (A) Schematic view of the P4-TO promoter generated by inserting two tetracycline
operator 2 (TetO2) elements into the P4 promoter of the hH-1 genome. TF, transcription factors. (B) DNA sequence of the P4-TOpromoter. The TATA box, the
two TetO2 elements, and the NS translation ATG start codon are highlighted.
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above, production of hH-1-TO virus in T-REx-293 cells was effi-
cient only when cultures were grown in the presence of DOX,with
a 60-fold reduction of virus titers in the absence of the inducer
(Fig. 2C). It should be noted, however, that the production of
hH-1-TO in the presence ofDOXwas about 6-fold lower than that
of hH-1, suggesting that the modifications introduced into the P4
promoter region slightly reduced the fitness of the virus in these
cells.
Generation of the Ad-PV chimera. The results presented
above prompted us to insert the entire parvovirus hH-1-TO ge-
nome into the DNA backbone of a replication-deficient adenovi-
rus vector (Ad5E1E3), thus generating the plasmid pAd-hH-
1-TO containing the chimeric vector genome. We first tested
whether the P4-TO promoter region kept its TetR sensitivity once
inserted into the Ad genome. For this purpose, T-REx-293 cells
were transfected with the pAd-hH-1-TO chimeric plasmid and
grown for 5 days with or without DOX. Total protein extracts
from these cells were then analyzed by Western blotting for the
presence of the parvoviral NS1 and VP proteins. As illustrated in
Fig. 3A, significant production of NS1 was detected only when
DOX was provided to the cells. Consistent with previous results
(Fig. 2A),NS1 expression correlatedwith an induction of VP1 and
VP2 capsid protein expression. These results confirmed the TetR
sensitivity of P4-TO gene expression in an Ad context.
We next investigated whether it was possible to produce
Ad-PV chimeric virions from the pAd-hH-1-TO construct. As a
negative control, we used the pAd-hH-1 vector containing the
wild-type P4 promoter (from which we previously failed to gen-
erate the chimeric virions), and, as a positive control, we used the
parental Ad plasmid whose E1 gene deletion is complemented by
the 293 cells used as producers. In a first round of production,
T-REx-293 cells were transfected with PacI-linearized pAd-hH-1-
TO, pAd-hH-1, or pAd plasmids and grown in medium with or
without DOX for 7 days before being lysed. Crude cell extracts
were then used to reinfect fresh T-REx-293 cells in two successive
rounds of virus amplification. The final cell lysates were then pu-
rified by cesium chloride (CsCl) gradient centrifugation and the
viral stocks titrated using an adenovirus replication assay. Virus
FIG 2 Characterization of the hH-1-TO virus. (A) Inducible expression of the phH-1-TO plasmid containing the P4-TO promoter. T-REx-293 cells, constitu-
tively expressing the Tet repressor, were transfectedwith either phH-1 or phH-1-TOmolecular clones and grown inmedium supplementedwithDOX (1g/ml)
() or were left unsupplemented (). After 48 h, total protein cell extracts were prepared from these cultures and analyzed byWestern blotting for the presence
of viral proteins (NS1 andVP) and actin (used as a loading control). (B) Infectiousness of the hH-1-TO virus. T-REx-293 cells were transfectedwith either phH-1
or phH-1-TOviral plasmids and grown for 1week in the presence or absence ofDOX.Cells were harvestedwithin theirmediumand lysed. Produced viruses were
further amplified by infecting NB324K cells. Cell lysates from these cultures were then analyzed for the presence of parvovirus particles by a plaque assay using
NB324K indicator cells. Representative images (5-cm-diameter areas) from the plaque assay are shown. (C) DOX dependence of hH-1-TO virus replication in
T-REx-293 cells. T-REx-293 cells, grown in 6-well plates, were infectedwith hH-1 or hH-1-TOviruses, at anMOI of 2,500 viral genomes (Vg) per cell, and further
grown in the presence or absence of DOX. After 4 days, cells were harvested within their medium and lysed through 3 freeze-and-thaw cycles. After elimination
of cellular debris by centrifugation, crude virus preparations were treated with Benzonase to remove free viral DNA and processed for parvovirus-specific qPCR.
Titers of hH-1 or hH-1-TO parvoviruses are expressed in Vg/milliliter.
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preparations were also subjected to electron microscopy analysis
to control their purity. Analysis of the crude cell lysates before Ad
purification showed that, in agreement with previous results, the
pAd-hH-1 chimeric vector failed to generate any detectable viral
particles. In contrast, chimeric viruses were produced in T-REx-
293 cells by transfecting the cells with pAd-hH-1-TO vector, un-
less DOXwas added to the cell culture medium (data not shown).
These results are in line with the evidence indicating that parental
NS proteins (most likely NS1) were responsible for the inhibition
of adenovirus chimeric virus replication. Remarkably, the pro-
duction of theAd-hH-1-TO (Ad-PV) chimeric viruses in the pres-
ence of functional TetR was very efficient, as it yielded titers sim-
ilar to Ad control titers after purification (Fig. 3B). Electron
microscopy analysis showed neither differences between Ad-PV
andAd control particles nor parvovirus contamination in the pro-
duced Ad-PV viral stocks (Fig. 3C). Taken together, these results
demonstrate that, by transiently blocking the parvoviral NS tran-
scription unit, it is possible to produce Ad-PV chimeric viruses at
high titers in the T-REx-293 packaging cell line.
Generation of infectious parvovirus particles from the
Ad-PV chimera. We then investigated whether fully infectious
parvoviruses were produced after infection of transformed target
cells with the Ad-PV chimeric viral particles. We used two cell
lines permissive for parvovirus production, namely, simian virus
40 (SV40)-transformed NB324K and cervical carcinoma-derived
SiHa cells. After infection with purified Ad-PV, crude cellular ex-
tracts were analyzed for the presence of infectious parvovirus par-
ticles by a plaque assay. In accordance with our initial working
hypothesis, autonomously replicating infectious parvoviruses
were produced upon infection of both NB324K and SiHa cells
with Ad-PV chimeric virions (Fig. 4A). H-1PV production is rou-
tinely carried out in two steps, first by transfecting HEK293 cells
with a plasmid harboring the viral genome, to produce an initial
virus batch, and then by amplifying this batch through infection of
NB324K cells for 3 to 4 days. We compared the yields of PV par-
ticles produced in NB324K cells following their infection with
equivalent genomic amounts of H-1PV and Ad-PV chimera. As
shown in Fig. 4B, similar PV titers were obtained irrespective of
whether producer cells were infected with H-1PV or Ad-PV chi-
meras. In order to verify whether PVparticles generated byAd-PV
chimera-infected cells in a cancer cell population are indeed able
to infect neighboring cells and multiply therein, we have carried
out “virus spread” assays in HeLa cells. In order to distinguish
between PV production during the first round of infection
(Ad-PV ¡ PV conversion) and total PV production, cells were
treatedwith neuraminidase (NA) or left untreated. At 10 h postin-
fection, NA is known to prevent H-1PV from binding to cell
plasma membrane, by catalyzing the hydrolysis of sialic acid, an
important component of the H-1PV receptor (1), and therefore
does not interfere with virus replication in preinfected cells while
inhibiting spreading of progeny virus and further amplification.
As shown in Fig. 4C, the PV yield at 72 h postinfection was signif-
FIG 3 Generation of Ad-PV chimeras. (A) Inducible gene expression from the chimeric pAd-hH-1-TO plasmid. T-REx-293 cells were transfected with
pAd-hH-1-TO plasmid and further grown in medium with or without DOX for 5 days. Cells were then lysed and total protein extracts analyzed by Western
blotting for the presence of parvovirus NS1 and VP proteins and -tubulin (loading control). No Trans., no transfection. (B) Ad-PV chimera production. In a
first round of production, T-REx-293 cells were transfected with the chimeric pAd-hH-1-TO plasmid or either of the parental pAd (pAd5E1E3) and
pAd-hH-1 plasmids and grown inmedium supplementedwithDOXorwithout supplementation. Cell lysates from these cultures were used for infection of fresh
T-REx-293 cells in a second round of production, and the procedure was repeated a third time by scaling up the volume of the culture flasks as described in
Materials andMethods. Viral stocks were purified twice throughCsCl gradient ultracentrifugation and titrated using anAdeno-XRapid Titer kit (Clontech), and
yields were expressed as Ad infectious units/milliliter (IU/ml). (C) Electron microscopy (EM) analysis of produced virions. EM images of the purified Ad-hH-
1-TO (Ad-PV), Ad, and hH-1-TO viruses are shown. Bars, 100 nm.
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icantly higher inHeLa cells cultured in the absence of NA, provid-
ing evidence of PV spreading in these cultures. It should also be
stated that PV yields in the presence of NA were similar for PV-
and Ad-PV-infected cells (data not shown). Altogether, these re-
sults indicated that the PV component of the Ad-PV chimera was
efficiently rescued from the chimera, resulting in primary PV pro-
duction which was followed by secondary rounds of PV amplifi-
cation. This was confirmed by measuring the capacity of the PV
particles generated and released by Ad-PV-infected cells to kill
neighboring cancer cells. HeLa cells were infected with Ad-PV at
low multiplicities of infection (MOIs) (0.2 and 0.4 IU/cell) and
then grown in the presence or absence of NA for 72 h before being
processed for LDH assays. As shown in Fig. 4D, only a small frac-
tion of cells was killed by the chimera when NA was added to the
culture medium after Ad-PV infection. This is consistent with the
fact that NA treatment prevents second rounds of infection,
thereby restricting killing to the fraction of cells initially hit by the
chimera. In contrast, the whole population of cells grown in the
absence of NA died within 72 h postinfection, indicating that PV
particles produced by chimera-infected cells were able to spread to
neighboring cancer cells and kill them efficiently (Fig. 4D). These
results provide a proof of concept that the Ad-PV chimera can be
used as a novel tool for the delivery of autonomous parvoviruses
to target cells and that, once brought into cells by the chimera, the
PV genome is released and initiates the de novo synthesis of fully
infectious parvovirus progeny particles.
Enhanced oncotoxic potential of the Ad-PV chimera. It is
known that H-1PV induces cytopathic effects on a large number
of cancer cells (reference 10 and our unpublished results). How-
ever, there are also cancer cell lineswhich areweakly susceptible or
completely refractory toH-1PV cytotoxicity (our unpublished re-
sults). Preliminary experiments showed that the hH-1 and hH-
1-TO parvoviruses exerted similar cytotoxic activities against
HeLa cells as measured by LDH assays, indicating that the modi-
fication introduced into the P4 promoter region did not modify
the oncolytic activity of the parvovirus (data not shown). The
cytotoxic activities of Ad-hH-1-TO (Ad-PV) chimera and both
parental viruses (Ad control [Adc] and hH-1-TO [PV]) were
compared using a panel of human cancer cell lines differing in
their sensitivities to H-1PV infection, including highly sensitive
FIG 4 Production, spreading, and cytotoxicity of progeny parvoviruses in cells infected with the Ad-PV chimera. (A) Parvovirus production. NB324K or SiHa
cells were infected with Ad-PV chimeras used at an MOI of 10 (NB324K) or 1 (SiHa), and culture media were renewed after 1 day to remove unbound viruses.
After further incubation for 4 to 5 days, cells were harvested within their medium and lysed. Crude virus preparations were analyzed for the presence of
parvoviruses by plaque assays. Titers of produced parvovirus are expressed in PFU/milliliter. (B) Parvovirus production and spreading. NB324K cells were
infectedwith equivalent genomic amounts of Ad-PV chimera orH-1PVwild-type virus (input, 10Vg/seeded cell). After 96 h, cells were collected in theirmedium
and subjected to three freeze-thaw cycles. After treatment with 50 U/ml of Benzonase for digesting cellular DNA and nonencapsidated viral DNA, crude cell
extracts were analyzed for their content of full viral particles by real-time qPCR, as described inMaterials andMethods. (C) Parvovirus spreading.HeLa cells were
infectedwithAd-PV chimeras (25Vg/cell). At 10 h postinfection, one set of dishes was treatedwith 0.1U/ml of neuraminidase (NA) in order to prevent second
rounds of parvovirus infection, while another set was left untreated ( NA). Benzonase-pretreated total cell lysates were analyzed by real-time qPCR for virus
particle content. (D) Parvovirus spreading and cytotoxicity. HeLa cells, grown in 96-well plates, were infectedwithAd-PV chimeras, treatedwithNA as described
for panel C or left untreated, and processed for LDH assay after 72 h.
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cells (cervical carcinoma-derived HeLa, melanoma pMelL),
poorly sensitive cells (lung cancer-derived A549), and resistant
cells (cervical carcinoma-derived ME-180, melanoma Lox-IMVI,
colon cancer HCT-15 and HCC-2998). In a first step, the suscep-
tibility of these cells to infection with Ad5 and H-1PV was deter-
mined by using recombinant viruses harboring the GFP reporter
gene (Ad-GFP or H-1-GFP). As illustrated in Fig. 5, fluorescence-
activated cell sorter (FACS) analysis performed 48 and 72 h after
infection revealed that Ad-GFP and H-1-GFP transduced HeLa
and A549 in similar manners whereas Ad-GFP was much more
efficient than H-1-GFP in transducing the cell lines previously
identified as resistant to H-1PV cytotoxicity. As expected, pMelL
cells (which lack the Ad receptors on their surface) were efficiently
transduced by H-1-GFP but not Ad-GFP (Fig. 5).
In a second step, viral cytotoxicity was evaluated by an LDH
assay (analysis of cell lysis), an MTT assay (analysis of cell viabil-
ity), and xCelligence (real-time analysis of cell growth). (i) The
cytotoxic activity of the Ad-PV chimera in HeLa cells was first
evaluated in comparison with that of the parental viruses
(Fig. 6A). Cells were infected with equal amounts of the different
viruses. In agreement with previous results, LDH andMTT assays
revealed that PV used singly or in combination with the Ad con-
trol killed HeLa cells very efficiently. A similar cytotoxic effect was
observed with the Ad-PV chimera, indicating that, under these
experimental conditions, the PV cytotoxic potential is preserved
upon PV delivery through the Ad vector. As the Adc alone was
much less toxic than PV (as expected from the lowMOI used and
from the fact that the Adc is a replication-deficient virus), we
concluded that the cytotoxicity of the chimeric Ad-PV in these
cells wasmainly due to the PV component (Fig. 6A). In agreement
with these results, analysis of the cell growth curves using the
xCelligence system showed that the Adc virus had a limited effect
on the proliferation of HeLa cells whereas the PV was able to
efficiently suppress the proliferation and induce death of these
cells (Fig. 7A). The results showing this striking HeLa cell growth
suppression and killing were achieved to a similar extent when the
PV was delivered by the chimera. It is worth noting that the cyto-
toxic effect of the Ad-PV chimera was delayed by approximately
24 h in comparison to the one induced by PV, which is consistent
with the time needed for PV rescue from the chimeric vector in
these cells. A549 cells were also found to be sensitive to both PV
and chimeric Ad-PV cytotoxicity, confirming that the oncolytic
potential of H-1PV is kept by the chimeric virus (Fig. 6B and Fig.
7B). In keeping with the fact that A549 cells are less susceptible to
H-1PV infection thanHeLa cells, a concentration of PV or Ad-PV
chimera that was 10 times higher was required in order to effi-
ciently kill these cells. (ii) We then tested whether the chimera is
able to kill tumor cells, namely,ME-180, Lox-IMVI, HCT-15, and
HCC-2998, previously identified as being resistant to direct
H-1PV infection (Fig. 6 and 7). LDH andMTT assays showed that
infections with Ad and PV viruses (used singly or in combination)
had little cytotoxic effect on these cells. In striking contrast, the
Ad-PV chimera was much more toxic and efficiently killed all
tumor cell lines analyzed, indicating that the chimera has im-
proved oncolytic activity compared to that of the parental viruses
from which it originated (Fig. 6C to F). Kinetic analyses showed
that the growth of the cell lines described above was only margin-
ally disturbed by PV, confirming their significant resistance to the
parvoviruses (Fig. 7C to F). On the other hand, the Adc virus had
various toxic effects in these cells, ranging from full growth sup-
pression (HCC-2998; see Fig. 7F) or growth retardation (ME-180;
see Fig. 7C) to full resistance (Lox-IMVI and HCT-15; see Fig. 7D
and E, respectively). Similar results were obtained with the Adc
used in combination with PV. Interestingly, the Ad-PV chimera
was found to be much more toxic than the parental viruses, al-
ready fully suppressing the growth of all cells and inducing strong
cytotoxic effects at 20 to 40 h postinfection (Fig. 7C to F). (iii) As
a control, the Ad-5 receptor-null pMelL cell line (30) was also
included in this analysis. As shown in Fig. 6G and 7G, these cells
were sensitive to PV cytotoxicity but completely resistant to both
the Adc and Ad-PV chimera, indicating that the chimera exerts
its cytotoxicity only in cells competent for Ad uptake (Fig. 6G
and 7G).
In a third step, it was important to verify that the tumor spec-
ificity of PV cytotoxicity was kept when the PV was delivered by
the Ad vector. To this end, the cytotoxicity of the chimera was
compared with that of its parental viruses in primary healthy hu-
man cells of different origins, namely, foreskin fibroblasts, oral
fibroblasts, melanocytes, and astrocytes, by LDH andMTT assays.
Despite the fact that Ad-GFP was more efficient than H-1-GFP at
transducing all the cell cultures tested (Fig. 8A), even after a longer
virus incubation compared with incubation of cancer cells (5 ver-
sus 4 days), healthy cells were found to be fully resistant (foreskin
fibroblasts) or only minimally sensitive (oral fibroblasts, melano-
cytes, and astrocytes) to the cytotoxic activity of the Ad-PV chi-
mera, in striking contrast with the above-mentioned high sensi-
tivity of cancer cells (Fig. 8B).
FIG 5 Transduction efficiency of recombinant Ad-GFP and H-1-GFP. The
indicated cells were infected with recombinant Ad or PV (1 TU/cell as quan-
tified by using HEK-293T cells) carrying the GFP reporter gene. After 48 and
72 h, cells were harvested and analyzed by flow cytometry. Values represent the
percentages of GFP-positive cells.
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FIG 6 Improved cytotoxic activity of Ad-PV chimera toward cancer cell lines. LDH and MTT assays were used to measure infected cell killing and
viability, respectively. HeLa (A), A549 (B), ME-180 (C), Lox-IMVI (D), HCT-15 (E), HCC 2998 (F), and pMelL (G) human cancer cells were seeded in
96-well plates and infected with Ad-hH-1-TO chimera (Ad-PV), Ad control (Adc) (MOI for both Ads were expressed as IU/cell), hH-1-TO (PV; expressed
as PFU/cell), or hH-1-TO in combination with Adc (PV  Adc) viruses at the indicated MOIs (expressed as IU/cell for Ad-PV and Adc or PFU/cell for
PV). Untreated cells () were used as the control. Values represent the percentages of lysed (LDH assay) or viable (MTT) cells calculated as described in
Materials and Methods.
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FIG 7 Enhanced toxicity of the Ad-PV chimera for cancer cell lines. HeLa (A), A549 (B), ME-180 (C), Lox-IMVI (D), HCT-15 (E), HCC 2998 (F), and pMelL
(G) human cancer cells were seeded in 96-well E-plates (xCelligence Roche) and infected at the indicated MOIs with Ad-hH-1-TO chimera (Ad-PV), Ad control
(Adc), hH-1-TO (PV), or hH-1-TO in combination with Adc (PVAdc) viruses. The proliferation curves of virus- versusmock-infected cells weremonitored in real
time using the xCelligence system. Cell index values are proportional to cell numbers and were recorded every 30min for amaximum of 1 week. Results are presented
as average values with relative standard deviation bars from triplicate measurements in a typical experiment. Arrows indicate the time of infection.
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FIG 8 Limited cytotoxicity of the Ad-PV chimera for healthy human primary cells. (A) Flow cytometry. Human foreskin fibroblasts, oral fibroblasts,
melanocytes, and astrocytes were infected with Ad-GFP or H1-GFP (1 GFP TU/cell). After 72 h, cells were harvested and subjected to flow cytometric
analysis for the quantification of GFP-positive cells. Mock-treated cells were used for setting fluorescence background values; HEK293T cells were used
as a positive control. (B) LDH andMTT assays. Human foreskin fibroblasts, oral fibroblasts, melanocytes, and astrocytes were seeded in 96-well plates and
infected with chimeric Ad-hH-1-TO (Ad-PV), Ad control (Adc), hH-1-TO parvovirus (PV), or a mixture of Ad control and hH-1-TO viruses (PV Adc)
or left uninfected (). After 5 days of incubation, percentages of lysed or viable cells were assessed by LDH and MTT assays, respectively, as described in
Materials and Methods.
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Altogether, these results show the improved oncolytic activity
of the Ad-PV chimera compared with Ad and PV parental viruses.
DISCUSSION
In this study, we constructed the first adenovirus-autonomous
parvovirus (Ad-PV) chimera by inserting the complete genome of
hH-1PV into the Ad5 genome deleted of the E1 and E3 regions
(Ad5E1E3). Our aim was to develop a system that combines
the most favorable features of adenovirus (high-efficiency gene
delivery, large packaging capacity, high titer production) and par-
vovirus (oncolytic and oncosuppressive properties and the ab-
sence of pathogenicity in humans). The project faced two major
challenges: (i) the production of chimeric adenovirus containing a
potentially interfering PV insert and (ii) the complete recovery of
the PV genome from the Ad backbone with the generation of fully
infectious PV particles exerting cytotoxic activity in cancer cells
but not in healthy cells. These two requirements proved to be
difficult to reconcile. Indeed, our first attempts to develop Ad-PV
chimeras failed at the production stage due to the strong negative
interference of parvoviral NS proteins with hybrid adenovirus
vector replication. This inhibitory effect has been previously re-
ported in another study where the production of adenovirus type
5 containing a parvovirus-expressing cassette (including the NS
transcription unit under the control of its natural P4 promoter
and the late parvoviral P38 promoter driving the expression of a
heterologous transgene) was possible only after silencing of par-
vovirus NS1 expression by means of antisense oligonucleotides
(28). However, this strategy was not successful in the present sys-
tem, as neither the use of antisense oligonucleotides nor the use of
siRNAs or shRNAs directed against NS1 (transiently transfected
as well as constitutively expressed in stable cell lines) allowed the
chimeras to be produced at significant titers (data not shown).
The explanation for this failuremay reside in the greater complex-
ity of our vector in comparison to the one previously published.
Indeed, the present chimera can be distinguished by the fact that it
comprises the entire PV genome, including NS1-specific nicking
sites at its extremities (17), and can thus be expected to be sensitive
to NS1-endonuclease activity. The presence of these sites is essen-
tial for NS1-mediated excision and release of the PV genome from
the adenovirus backbone in target cancer cells but may also pre-
clude hybrid adenovirus genome replication in producer cells by
allowing NS1 to disrupt the adenovirus backbone. Similar techni-
cal limitations were also encountered in the generation of adeno-
virus-AAV chimeras, where the expression of the Rep 78 gene
precluded adenovirus replication (34) andmaturation by colocal-
izing to the Ad replication centers (35). Our initial failure to pro-
duce the Ad-PV chimera suggested that even very low levels of
NS1 were sufficient to interfere with Ad vector replication. We
circumvented this problem by inserting tetracycline operator se-
quences (15, 36) into the PV P4 promoter in order to tightly con-
trol NS1 expression. In T-REx-293 cells, which constitutively ex-
press the Tet repressor (TetR), the activity of P4-TO was
drastically suppressed. As a consequence, in parvovirus H-1TO-
transfected and -infected T-REx-293 cells in the absence of DOX
inducer, no or little expression of NS1 protein and virus produc-
tionwere detected. In contrast, in tumor cells not expressing TetR,
expression of NS1 and the overall fitness of the modified parvovi-
rus were only slightly reduced in comparison with wild-type
H-1PV results. Thus, we identified a positionwithin theH-1PVP4
promoter at which a foreign sequence (in our case, sequences of
Tet-responsive elements) can be inserted to modify the function-
ality of the promoter without jeopardizing the overall replication
and fitness of the virus in permissive cells. This finding may pave
the way for further engineering of the P4 promoter through inser-
tion into the same site of other sequences that could improve
cancer-specific transcription and replication of H-1PV. As the
present Tet-responsive element addition makes NS1 expression
inducible, the H-1PV-TO virus could also be used in studies aim-
ing to further characterize the role of NS proteins in the viral life
cycle and associated cytopathic effects.
The results we obtained prompted us to introduce the modi-
fied parvovirus genome into the Ad genome, resulting in the con-
struction of the Ad-hH-1-TO chimera (Ad-PV). Consistent with
our initial hypothesis, the Ad-PV chimera was produced at high
titers in T-REx-293 cells. Furthermore, this chimera efficiently
delivered its PV component to cancer cells in which the parvoviral
genome was excised from the vector and replicated autono-
mously, yielding infectious progeny PV particles. Rescue from the
Ad backbone was probably facilitated by the fact that the inserted
H-1 genome (hH-1) contains an extra consensus NS1 nick site at
the left-hand viral terminus (17). Most remarkably, the Ad-PV
chimera was more efficient in killing various cancer cell lines than
the parental PV or Ad (used alone or in combination). Themech-
anisms underlying this improved cytotoxicity are still a matter of
speculation and may differ from one cell line to another. In some
tumor cells, the greater efficiency of Ad-PV may reside, at least in
part, in the higher capacity of Ad (and therefore of the chimera)
for initiating infection compared to that of the PV. Indeed, exper-
iments performed with recombinant Ad and PV viruses express-
ing GFP showed that some PV-resistant cells could be more effi-
ciently transduced by the Ad. The Ad chimera may be more
competent than the PV for delivering the parvoviral genome into
the nucleus of such cells as the result of using a distinctmechanism
of particle uptake. If so, it may be due to differences between Ad
and PV in their recognition of critical cellular factors involved in
virus cell-binding and entry (i.e., receptors or coreceptors) or re-
quired for the trafficking of the virus from the cell surface to the
nucleus. Amore efficient Ad-PV chimera-mediated delivery of the
PV genome into the nucleus of infected cells can be expected to
result in enhanced PV gene expression, leading to an increase in
the production of cytotoxic NS1 protein and in the induction of
oncolysis. The Ad component of the chimera could also assist
parvovirus replication in cancer cells at levels other than entry and
nuclear trafficking. We have recently shown that specific Ad
genomic elements stimulate recombinant PV production bymore
than 100-fold (10). Similarly, Ad enhances the production of the
human B19 parvovirus (14). Ad also has the ability to counteract
the innate immune response (19). However, the fact that Ad and
PV coinfection did not kill cancer cells as effectively as infection by
the chimera argues against these mechanisms being major con-
tributors to the higher cytotoxic activity of the chimera. Further
studies are needed to unravel the mechanism(s) behind the im-
proved oncolytic potential of the chimera. It is also worth men-
tioning that, although the Ad virus was transducing healthy cells
(e.g., human primary astrocytes) more efficiently than the PV, the
Ad-PV chimera was of low toxicity to these cells, in keeping with
the specificity of PV cytotoxicity for transformed cells (25).
The present Ad-PV chimera is a prototype which is open to
further development. (i) It allows new approaches to be consid-
ered in order to increase the cancer specificity of PV-based treat-
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ments, taking advantage of the Ad-retargeting technology.
Indeed, tumor-retargeted Ads can be obtained by inserting can-
cer-specific retargeting ligands or adaptors (peptides, single-chain
antibodies, Affibody molecules, etc.) into the Ad capsid (20).
These retargeted Ads could be used for the development of a sec-
ond generation of Ad-PV chimeras that would act as vehicles for
the delivery of PV genomes into cancer cells only. This would be of
great benefit to circumvent the uptake of PVs by healthy cells,
which results in the sequestration of a major fraction of the PV
inoculum (7). (ii) The chimera might represent a valid solution
for treatment of tumors that are heterogenous with respect to
virus receptors. In this way, cells less susceptible to PV infection
could be targeted by theAd-PV chimera and the released PVprog-
eny particles could in their turn infect cells poorly expressing the
Ad receptor(s) at their cell surface. (iii) Beside its use to improve
the specificity of infection, the adenoviral component of Ad-PV
chimeras gives the possibility of inserting large transgenes in the
Ad backbone, which cannot be done with PVs without making
them replication incompetent (6). It should be possible in this way
to arm the chimera with therapeutic transgenes that reinforce the
intrinsic PV cytotoxic activity and/or increase the PV ability to
replicate in cancer cells. (iv) Another development of the Ad-PV
chimera may take advantage of the availability of Ad serotypes
(33). This should allow serologically distinct Ad-PV chimeras to
be generated and used sequentially in clinical protocols in order
to escape neutralization by antiviral antibodies. (v) In addition to
providing the versatility mentioned above, the use of adenoviral
vectors as PV carriers may help to improve the production of PVs
andPV-based vectors. Indeed, aswith any other Ad-based vectors,
it should be possible to produce the Ad-PV chimeras in the large
amounts and under the GMP conditions compatible with clinical
needs.
On the other hand, the chimera was shown to possess strong
cytotoxic activity. This is likely due to (i) the expression of the
cytotoxic parvoviral NS1 protein, which is known to be especially
deleterious to oncogene-transformed cells (24), and (ii) the gen-
eration of progeny PV particles, which spread in the tumor cell
population and induce secondary rounds of lytic infection, ampli-
fying the initial cytotoxic activity of the chimera.
In conclusion, this report adds a promising new tool to the
arsenal of oncolytic viruses. Extension of the present in vitro
investigation to animal tumor models is to be conducted in the
future with the intention of producing a proof of concept that
may justify the further clinical assessment of oncolytic virus
chimeras.
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